0443 GMT - Venture Corp.'s lifestyle and consumer products, as well as life sciences segments are likely to recover in 2027, supporting its earnings, says DBS Group Research's Lee Keng Ling in a note. The Singapore technology company is expected to launch a product in 4Q under its lifestyle and consumer products division, which should support the business's volume recovery and higher product value, the analyst says. Meanwhile, its life sciences segment is stabilizing from a recent downturn and should turn into a growth avenue around 2027, she says. DBS raises its 2026-2028 earnings estimates by 4%-5%. It raises its target price to 22.90 Singapore dollars from S$21.80 and maintains a buy rating. Shares rise 0.7% to S$16.78.